Enhabit Inc. (EHAB)vsNovartis AG ADR (NVS)
EHAB
Enhabit Inc.
$13.80
+0.07%
HEALTHCARE · Cap: $706.91M
NVS
Novartis AG ADR
$143.57
+1.32%
HEALTHCARE · Cap: $271.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5224% more annual revenue ($56.69B vs $1.06B). NVS leads profitability with a 22.5% profit margin vs -0.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
EHAB
Hold39
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EHAB.
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$143.57
$50.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
1.9% revenue growth
2.9% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : EHAB
The strongest argument for EHAB centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : EHAB
The primary concerns for EHAB are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
EHAB profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
EHAB carries more volatility with a beta of 0.96 — expect wider price swings.
EHAB is growing revenue faster at 1.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enhabit Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Enhabit, Inc. provides home health and hospice services in the United States.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?